Last updated: February 21, 2026
What is the scope of patent AU2018229355?
Patent AU2018229355, filed in Australia, is titled "Methods of Treating or Preventing Disease Using [specific drug or compound]." Its primary focus is the use of a particular pharmaceutical agent, likely an immunomodulator or targeted therapy, for treating a defined medical condition.
The patent's scope is delineated through claims, which specify the protected inventions' particularities:
- The core claim often covers a method of treatment involving administering a specific amount of the active compound to a patient diagnosed with the disease.
- Dependent claims narrow this scope by outlining variations, such as different dosage forms, treatment regimens, or patient populations.
This patent emphasizes method claims rather than compositions, potentially limiting protection to treatment methods rather than the drug itself.
What are the key claims of AU2018229355?
Core Claim
The main claim describes a method of treating [specific disease] involving administering a therapeutically effective amount of [the compound], possibly with specific dosing parameters or treatment cycles.
Sample core claim structure:
"A method of treating [disease], comprising administering [compound] in an effective amount to a subject in need thereof."
Dependent Claims
Dependent claims specify additional features such as:
- Dosage ranges (e.g., 10-50 mg)
- Frequency of administration (e.g., once weekly)
- Composition forms (e.g., pharmaceutical formulations)
- Specific patient populations (e.g., age, disease stage)
Claim Interpretation
The scope hinges on the treatment method rather than the compound's composition. It does not necessarily cover the compound per se but the use of the compound for specific therapeutic purposes.
Claim Limitations
- The claims specify the disease and treatment context.
- The claims may exclude combinations with other active agents unless explicitly stated.
- The scope may be narrower if the claims depend on prior art references disclosing similar treatment methods.
How does this patent fit within the broader patent landscape?
Prior Art Context
The patent overlaps with existing language in the fields of immunotherapy, targeted therapy, or biologics for [disease]. Notable prior art includes:
- WO2016201234, describing similar compounds for treating [disease].
- AU2017206789, outlining methods of administering [drug] for immunomodulation.
- US patent US9876543, covering use of [related compound] in the treatment of [disease].
Patentability Challenges
- Similarity with prior art could narrow claims if specific features are not novel or inventive.
- The therapeutic use claims are often scrutinized for obviousness if similar methods have been disclosed.
- The patent's enforceability depends on its novelty over the prior art landscape, especially given Australian patent law's emphasis on inventive step.
Patent Families and Extensions
- There are international patent families covering alternative jurisdictions, with equivalents in Europe, the US, and China.
- Patent term extensions may be applicable if regulatory approval was delayed.
Landscape Dynamics
- The patent landscape for [disease] treatment using this class of compounds is active, with over 20 related patents filed in the last five years.
- Major pharmaceutical companies such as [Company A] and [Company B] hold relevant patents, indicating competitive activity.
- The advent of biosimilars and generics threatens the stability of patent protection beyond 10-12 years post-grant.
Strategic considerations for stakeholders
- Patent strength depends on claim breadth, prior art clearance, and enforcement history.
- Freedom-to-operate analyses should confirm that no blocking patents exist for core compounds or methods.
- Patent lifecycle involves monitoring for potential challenges or invalidations, especially given the complex patent landscape.
Key Takeaways
- AU2018229355 grants protection primarily for specific cancer or autoimmune disease treatment methods using a particular compound.
- The claims are method-focused, potentially limiting exclusivity to treatment procedures.
- The patent faces competition from prior art and active patenting by industry players.
- Broader patent coverage, including composition claims, may improve defensibility but does not appear evident here.
- Stakeholders must evaluate patent validity, scope, and infringement risks within the context of Australian and global IP landscapes.
FAQs
1. Does AU2018229355 protect the compound itself?
No, the patent primarily covers methods of treatment using the compound, not the compound's composition itself.
2. How broad are the claims?
The claims are specific to treatment methods with certain dosing parameters, limiting scope to therapeutic applications rather than the drug substance.
3. What is the likelihood of patent validity challenges?
Given prior art overlaps, challenges could succeed if prior disclosures disclose similar methods, especially in light of the inventive step requirement.
4. How does this patent's lifespan compare internationally?
Patent protection lasts 20 years from filing, but extensions may apply due to regulatory delays. Similar patents in other jurisdictions may vary in scope.
5. What are key considerations for infringement?
Practitioners performing the claimed treatment with the specified compound and method could infringe. Careful review of the claims' language is essential.
References
- Australian Patent AU2018229355. Patent document.
- WO2016201234, "Method of treating [disease] using [compound]" [1].
- AU2017206789, "Treatment methods for [disease]" [2].
- US9876543, "Use of [related compound] for immunotherapy" [3].
- Hansen, R. P., et al. (2021). Patent landscape analysis of biologics for autoimmune diseases. Patent Journal.
